• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用体外平行四边形方法为未研究的药物中间体设定职业接触限值。

Setting occupational exposure limits for unstudied pharmaceutical intermediates using an in vitro parallelogram approach.

机构信息

Cambrex Corporation, 1205 11th Street, Charles City, IA 50616, USA.

出版信息

Toxicol Mech Methods. 2011 Feb;21(2):76-85. doi: 10.3109/15376511003638280. Epub 2010 Feb 15.

DOI:10.3109/15376511003638280
PMID:20156007
Abstract

Occupational exposure limits for unstudied pharmaceutical synthetic intermediates are often established under the assumption that penultimate and near-ultimate intermediates have the same structure-activity and dose-response as the ultimate active pharmaceutical ingredient (API). This is seldom the case because moieties that render biological activity to the API are often protected or modified for synthetic purposes. Incorrectly assuming that intermediates have biological activity similar to the API may lead to excessive exposure controls that in turn impose unnecessary ergonomic hazards on workers and greatly reduces the scale and efficiency of production. Instead of assuming intermediates have the same toxicity profile as the API, it is feasible to use a parallelogram approach to establish exposure limits for synthetic intermediates using low-cost in vitro data. By comparing in vitro responses of intermediates to structurally similar data-rich molecules such as the API, occupational exposure categories can be established for unstudied intermediates. In this contribution (1) methods for setting occupational exposure limits for data-poor compounds are reviewed; (2) applications and limitations of in vitro assays are discussed; (3) two exposure categorization examples are presented that rely on an in vitro parallelogram approach; and (4) inherent safeguards for uncertainties in pharmaceutical risk assessment are identified. In vitro hazard and dose-response information for unstudied intermediates that are structurally similar to well-studied APIs can greatly enhance the basis for setting occupational exposure limits for unstudied synthetic intermediates.

摘要

对于未经研究的药物合成中间体,职业暴露限值通常是在假定前体和近体中间体与最终的活性药物成分(API)具有相同的结构-活性和剂量-反应的假设下建立的。这种情况很少见,因为赋予 API 生物活性的部分通常为了合成目的而被保护或修饰。错误地假设中间体具有与 API 相似的生物活性可能导致过度的暴露控制,这反过来又给工人带来不必要的人体工程学危害,并大大降低了生产的规模和效率。与其假设中间体具有与 API 相同的毒性特征,不如使用平行四边形方法使用低成本的体外数据为合成中间体建立暴露限值。通过比较中间体与 API 等结构相似的、数据丰富的分子的体外反应,可以为未经研究的中间体建立职业暴露类别。在本研究中(1)回顾了为数据匮乏的化合物设定职业暴露限值的方法;(2)讨论了体外检测的应用和局限性;(3)提出了两个依赖于体外平行四边形方法的暴露分类示例;(4)确定了药物风险评估中不确定性的内在保护措施。与经过充分研究的 API 在结构上相似的未经研究的中间体的体外危害和剂量-反应信息,可以大大增强为未经研究的合成中间体设定职业暴露限值的基础。

相似文献

1
Setting occupational exposure limits for unstudied pharmaceutical intermediates using an in vitro parallelogram approach.采用体外平行四边形方法为未研究的药物中间体设定职业接触限值。
Toxicol Mech Methods. 2011 Feb;21(2):76-85. doi: 10.3109/15376511003638280. Epub 2010 Feb 15.
2
Strategies for preventing occupational exposure to potent compounds.预防接触强效化合物的职业暴露策略。
Toxicol Mech Methods. 2011 Feb;21(2):93-6. doi: 10.3109/15376516.2010.484621. Epub 2010 May 27.
3
Guidance on the establishment of acceptable daily exposure limits (ADE) to support Risk-Based Manufacture of Pharmaceutical Products.支持基于风险的制药产品制造的可接受日暴露限值 (ADE) 建立指南。
Regul Toxicol Pharmacol. 2013 Mar;65(2):242-50. doi: 10.1016/j.yrtph.2012.12.007. Epub 2013 Jan 3.
4
A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations.制药生产中可接受日暴露量应用的协调工作——操作考量
Regul Toxicol Pharmacol. 2016 Aug;79 Suppl 1:S39-47. doi: 10.1016/j.yrtph.2016.06.001. Epub 2016 Jun 3.
5
Setting occupational exposure limits for pharmaceuticals.设定药品的职业接触限值。
Occup Med. 1997 Jan-Mar;12(1):67-80.
6
Establishing guidance for the handling and containment of new chemical entities and chemical intermediates in the pharmaceutical industry.为制药行业中新化学实体和化学中间体的处理与控制制定指南。
Occup Med. 1997 Jan-Mar;12(1):49-65.
7
Genotoxicity of 1,3-butadiene and its epoxy intermediates.1,3 - 丁二烯及其环氧中间体的遗传毒性。
Res Rep Health Eff Inst. 2009 Aug(144):3-79.
8
Performance-based exposure control limits for pharmaceutical active ingredients.
Am Ind Hyg Assoc J. 1996 Jan;57(1):33-42. doi: 10.1080/15428119691015197.
9
Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure.用于辅助设定职业接触限值的药物中间体致突变性评估策略
Regul Toxicol Pharmacol. 2015 Nov;73(2):515-20. doi: 10.1016/j.yrtph.2015.10.001. Epub 2015 Oct 8.
10
Occupational toxicology: test methods and approaches for the pharmaceutical industry.职业毒理学:制药行业的测试方法与途径
Occup Med. 1997 Jan-Mar;12(1):119-29.

引用本文的文献

1
Characterizing risk assessments for the development of occupational exposure limits for engineered nanomaterials.对工程纳米材料职业接触限值制定的风险评估进行特征描述。
Regul Toxicol Pharmacol. 2018 Jun;95:207-219. doi: 10.1016/j.yrtph.2018.03.018. Epub 2018 Mar 21.
2
A quantitative framework to group nanoscale and microscale particles by hazard potency to derive occupational exposure limits: Proof of concept evaluation.一种根据危害潜力对纳米级和微米级颗粒进行分组以推导职业接触限值的定量框架:概念验证评估。
Regul Toxicol Pharmacol. 2017 Oct;89:253-267. doi: 10.1016/j.yrtph.2017.08.003. Epub 2017 Aug 5.
3
A multi-stakeholder perspective on the use of alternative test strategies for nanomaterial safety assessment.
多利益相关方视角下的纳米材料安全评估替代测试策略的应用。
ACS Nano. 2013 Aug 27;7(8):6422-33. doi: 10.1021/nn4037927. Epub 2013 Aug 7.
4
Photodynamic therapy: occupational hazards and preventative recommendations for clinical administration by healthcare providers.光动力疗法:医疗保健提供者临床应用中的职业危害及预防建议
Photomed Laser Surg. 2013 Aug;31(8):398-407. doi: 10.1089/pho.2013.3496. Epub 2013 Jul 16.